Answers are grounded in this paper and cite their sources.
Adult gliomas are shaped by an interaction between somatic genetics and developmental cell identity rather than by either factor alone. Here, we distinguish cell-of-mutation, cell-of-origin, developmental lineage identity, and transcriptional cell state, and use this framework to compare isocitrate dehydrogenase (IDH)-mutant glioma with IDH-wildtype glioblastoma. Recent single-cell, spatial, and lineage-tracing studies show that glioma cells repeatedly co-opt neurodevelopmental programs, while genetic alterations bias, but do not fully define, the states that malignant cells occupy. Microenvironmental signals and therapy further reshape these states during tumor progression. We discuss how genetically engineered mouse models, patient-derived xenografts and tumoroids, and human organoid transplantation can test these relationships, emphasizing that complementary models and direct benchmarking to patient tissue are essential for resolving, and effectively treating, glioma heterogeneity.
No takes yet. Share an insight, caveat, or question.
Bristow et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: